MedTrace Logo

Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedure

NCT02628509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-05-22

No results posted yet for this study

Summary

The WITAVI study was designed to explore the kinetic and associated outcome of Von Willebrand Factor-multimerizaton defects associated with devices in cardiovascular diseases.

Conditions

Interventions

DEVICE

cardiac devices

patients receiving mechanical circulatory support or undergoing trans aortic valve replacement

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Sophie Susen, MD, PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-01
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02628509 on ClinicalTrials.gov